← Back to patent-cliff list
CAS 184972-09-6
(8R,9S,10R,13S,14S)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione
Codes: EXEM-005
Application context (from source-drug indications)
Breast cancerExemestaneDuctal carcinomaExemestane共济失调性毛细血管扩张Exemestane增生ExemestaneNon-small cell lung cancerExemestaneCervical intraepithelial neoplasiaExemestane
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Exemestane | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione→pyrrolidine→(1S,8R,9S,10R,13S,14S)-10,13-dimethyl-1,3-di(pyrrolidin-1-yl)-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17(2H)-one→(8R,9S,10R,13S,14S)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.